Acute Severe Colitis: Infliximab and/or Cyclosporine?

Author(s): Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino, Dario Sorrentino

Journal Name: Current Drug Targets

Volume 12 , Issue 10 , 2011

Become EABM
Become Reviewer

Abstract:

Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%.

As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

Keywords: Severe Colitis, Corticosteroids, Cyclosporine, Infliximab, Colectomy, Sigmoidoscopy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 10
Year: 2011
Page: [1448 - 1453]
Pages: 6
DOI: 10.2174/138945011796818234
Price: $65

Article Metrics

PDF: 5